Invention Grant
- Patent Title: Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use therof
-
Application No.: US15889296Application Date: 2018-02-06
-
Publication No.: US10227346B2Publication Date: 2019-03-12
- Inventor: Mark Edward Schnute , Andrew Christopher Flick , Peter Jones , Neelu Kaila , Scot Richard Mente , John David Trzupek , Michael L. Vazquez , Goran Mattias Wennerstal , Li Xing , Edouard Zamaratski , Liying Zhang , Rayomand Jal Unwalla
- Applicant: Pfizer Inc.
- Applicant Address: US NY New York
- Assignee: Pfizer Inc.
- Current Assignee: Pfizer Inc.
- Current Assignee Address: US NY New York
- Agent James Wasicak
- Main IPC: A61K31/437
- IPC: A61K31/437 ; A61K31/4353 ; C07D471/04 ; C07D401/14
Abstract:
The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
Public/Granted literature
- US20180170928A1 Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof Public/Granted day:2018-06-21
Information query
IPC分类:
